Actively Recruiting
Evaluation of ex Vivo Drug Combination Optimization Platform in Recurrent High Grade Astrocytic Glioma
Led by National University Hospital, Singapore · Updated on 2025-09-23
10
Participants Needed
2
Research Sites
197 weeks
Total Duration
On this page
Sponsors
N
National University Hospital, Singapore
Lead Sponsor
N
National University of Singapore
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is an interventional, non-randomized, single site study. Brain tumor samples will be collected from patients for organoids generation and subject to panel drugs screening and QPOP analysis to derive the optimal drug combinations for treatment at the time of first high grade astrocytic glioma recurrence. The investigators hypothesize that patient-derived organoids (PDOs) mimic the biological characteristics of high grade astrocytic gliomas and serve as an ideal platform for the evaluation of drug sensitivities, accurately reflecting the patient's therapeutic response to the drugs.
CONDITIONS
Official Title
Evaluation of ex Vivo Drug Combination Optimization Platform in Recurrent High Grade Astrocytic Glioma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 21 years of age or older with ECOG performance status 0 to 2 and life expectancy over 3 months with suspected or confirmed high grade astrocytic glioma
- Able and willing to provide signed informed consent before any study procedures
- Patients planned for standard-of-care treatment with surgery/biopsy followed by temozolomide and radiotherapy
- Documented tumor progression suitable for second line systemic therapy
- Sufficient tumor tissue available for organoid generation and at least one QPOP result available or pending
- Adequate bone marrow, liver, and kidney function as specified by laboratory criteria
- Capable of swallowing tablets
- Recovery from previous treatment-related toxicity to grade 0 or 1 except alopecia, or back to baseline preceding prior treatment
You will not qualify if you...
- Receipt of chemotherapy, radiotherapy, surgery, immunotherapy, or other therapy within 2 weeks before study entry
- Pregnancy or breastfeeding at the start of systemic anti-cancer therapy
- Women of childbearing potential must have a negative pregnancy test and agree to use contraception, as must men
- Concurrent cancers distinct from the study cancer except certain treated or low-risk cancers
- Presence of leptomeningeal disease or pure spinal high grade gliomas
- Kidney disease preventing safe MRI scans with gadolinium contrast
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Department of Hematology-Oncology, National University Hospital
Singapore, Singapore, 119074
Actively Recruiting
2
Ng Teng Fong General Hospital
Singapore, Singapore, 609606
Not Yet Recruiting
Research Team
A
Andrea Wong
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here